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Figure 2. Lung ﬁbrosis in NSG mice 8 weeks after transplantation
The lung from NSG mouse bearing PBMCs (A) or CD34+ cells (B) 8 weeks after transplantation was stained with Masson’s trichrome. Fibrosis is shown in blue.
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airways in the lung despite showing no sign of acute illness
or weight loss. Masson’s trichrome revealed increased
ﬁbrosis in the lung (Figure 2), but not in other organs.
Conclusion: We have shown that in the NSG mouse, a
combination of Cy/TBI with a lownumber of G-CSFmobilized
human PBMCs causes chronic lung inﬂammation and ﬁbrosis
that can serve as an important pre-clinic model of lung
cGVHD.415
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Introduction: Transplants from cord blood stem cells is
known to have lower incidence of graft-versus-host disease
(GVHD). However, in patients who undergo cord blood
transplant (CBT) and develop GVHD, its features are not well
studied.
Objectives: Determine clinical features of GVHD and dura-
tion of therapy in patients who received CBT.
Patients and Methods: From 1993 to 2013, 196 patients
received CBT were retrospectively analised and divided into
two categories. Group 1: 64 patients who developed GVHD.
Group 2: 132 patients without this complication. Acute
GVHD was graded according to Glucksberg criteria and
Chronic Graft versus Host Disease was graded by NIH
consensus criteria. Statistical analysis: Kaplan Meier (sur-
vival) and Fisher test (comparison of categorical variables). P
level of signiﬁcance was <0.05.
Results: Thirty three percent of patients developed GVHD
(40 males and 24 females). Median age was 6 years old (1-
31). 61 patients received CBT from a mismatched donor.
Thirty (48%) were transplanted for malignancies. Five
transplants were from a related and 59 from an unrelateddonor. Conditioning: Reduced intensity (RIC) in 6 cases and
myeloablative in 58. Engraftment was complete in 48 cases
(75%). Median survival in group 1 was 1832d (27-7283)
versus 201d in group 2 (1-6242). Twenty nine patients have
died. Forty one patients developed acute GVHD (aGVHD), 6
patients classic chronic GVHD (cGVHD) and 17 had an over-
lap syndrome. Grade II-IV aGVHD was seen in 49 cases
(84.4%). Among cGVHD patients 9 (39.2%) were mild, 6 (26%)
moderate and 8 (34.8%) severe. Median time for the onset of
aGVHD was 23d (7-227) and cGVHD was 176d (64-659). The
main sites of aGVHD were skin: 55(86%), gut: 22 (34%) and
liver:14 (21%). Among cGVHD patients, 14 had skin (21%),
liver:12 (18%), mouth:9 (14%), gut and lung (BO): 6(9%) each.
Median time of cyclosporine therapy was 923d (7-3365).
Steroids were used for a median time of 290d (8-4303).
GVHD was less common in patients with a full match donor
(p¼0,001), those who used thymoglobuline (p<0,0001) and
methotrexate (MTX) (p¼0,0133). In contrast, GVHD rates
were higher in patients who had an early (p¼0,0111) and
complete (p<0,0001) engraftment and had bacterial
(p¼0,0133) or viral (p¼0,0086) infections during the pre-
engraftment time. Survival rates were higher in patients who
developed GVHD (p¼0,0256), had a myeloablative condi-
tioning regimen (p¼0,048), children <14 yo (p¼0,0002),
patients who used cyclosporine for at least one year
(p<0,0001) and full chimerism (p<0,0001).
Conclusions: We conclude GVHD can be frequent and even
serious in CBT recipients. Risk factors included early and
complete engraftment, mismatched donor, viral or bacterial
infection during the pre-engraftment period, use of RIC and
lack of MTX. Risk factors for survival were absence of GVHD,
RIC, older age, and lack of full engraftment.416
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Background: Acute graft-versus-host disease (GVHD) re-
mains a leading cause of morbidity and mortality in alloge-
neic hematopoietic stem cell transplant (HSCT) recipients.
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effects of vitamin D may play a role in ameliorating acute
GVHD pathogenesis. Vitamin D has been shown to suppress
Th1 and Th17 cytokine production, inhibit differentiation and
maturation of dendritic cells, promote Th2-cell development,
and increase expression of regulatory T-cells. We performed
a retrospective analysis to evaluate whether serumvitamin D
levels on day 30 after HSCT are predictive of organ-speciﬁc
GVHD.
Methods: Fifty-four patients undergoing allogeneic HSCT
at the University of Pennsylvania between January 2008
and December 2012 were included in the analysis.
Serum 25-hydroxyvitamin D (25OHD) concentrations were
determined on day 30 following HSCT. We analyzed pa-
tients in two groups according to their median day-30
25(OH)D concentration (<20 and 20 ng/mL). The asso-
ciations between vitamin D levels and other variables were
conducted using Pearson correlations and t-tests. We then
used a landmark analysis to estimate the impact of day 30
vitamin D levels on subsequent clinical outcomes. Univar-
iate analyses were performed using cumulative incidence
and Cox regression analyses. Multivariable models were
constructed using the backward elimination method. We
also conducted immunophenotyping of day-30 peripheral
blood samples on patients who had low vs. normal vitamin
D levels.
Results: The median 25(OH)D concentration on day 30 was
20 ng/mL (range 6 - 50), reﬂecting severe vitamin D deﬁ-
ciency in half of the patients. Vitamin D levels signiﬁcantly
correlated with age, disease type, need for TPN during
transplant and day-30 albumin levels. In multivariate anal-
ysis of outcomes, day-30 vitamin D levels inversely corre-
lated with risk of acute skin GVHD (HR 0.27; 0.07 e 1.01;
p¼0.05). This associationwas speciﬁc to patients undergoing
reduced-intensity conditioned (RIC) HSCT (p<0.001) and not
myeloablative HSCT (p¼0.44). Vitamin D deﬁcient patients
expressed > 4-fold higher levels of CCR4, a skin-homing
receptor, on peripheral blood T-cells as detected on ﬂow
cytometric analysis (p¼0.036). Day 30 vitamin D levels didnot signiﬁcantly impact the risk of gastrointestinal (HR 2.16;
0.76e 6.09; p¼0.15) or hepatic GVHD (HR 0.31; 0.078e 1.24;
p¼0.1). No differences were observed in overall acute grade
2-4 GVHD, chronic GVHD, OS or non-relapse mortality.
Conclusion: Vitamin D deﬁciency on day 30 after allogeneic
HSCT is associated with signiﬁcantly increased risk of grade
2-4 cutaneous acute GVHD and increased expression of CCR4
on peripheral blood T-cells in patients undergoing RIC HSCT.
Vitamin D may confer a protective effect against acute skin
GVHD via reduction in CCR4 expression.417
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The therapeutic potential of allogeneic stem cell trans-
plantation (allo-SCT) in patients with malignant diseases of
the hemato-lymphatic system is thought to depend apart
from conditioning with high dose therapy on the anti-tu-
mor effect provided by the immune system of the donor.
However, the immune system of the donor may exert severe
and difﬁcult to control graft-versus-host-disease (GvHD).
Efforts to dissect GvHD and graft versus-leukemia/lym-
phoma reactions (GvL) have remained dissatisfying. Here,
we report immune reactions observed after allo-SCT sug-
gesting that GvHD and GvL are related rather quantitatively
and correspond with achieving 100% donor chimerism
allowing the extinction of remaining host immune cells
regardless whether malignant or not. Clinical ﬁndings: A
patient wit relapsed T-PLL was treated with allo-SCT and
received stem cells from a matched unrelated donor (MUD).
After being in complete cytological and molecular remis-
sion she relapsed molecularly on day +351. The molecular
analysis revealed malignant cells at the level of 0.16% in the
blood. While alemtuzumab was used for bridging, on day
+383 a ﬁrst donor lymphocyte infusion (DLI) was applied.
Despite a second and third DLI application later, a steady
increase in the MRD level above 2x10-2 was noted. How-
ever, the fourth DLI application on could not be given
because the patient had developed acute GvHD of the skin.
At the same time MRD no longer was detectable by RQ-PCR
with a detection limit below 1x10-5. GvHD resolved upon
treatment and the patient is in continuous complete
remission for more than 5 years. Likewise, a quantitative
effect in the balance between donor and host immune cells
was observed when a patient received an ABO blood
group major incompatible graft from a MUD. Frequently,
in those situations a delayed recovery of the major in-
compatible erythropoiesis is observed due to persisting
isohemagglutinin producing donor cells. Here, even after
complete tapering of the immunosuppression and thera-
peutic approaches including rituximab anemia persisted.
After DLI application, the patient developed acute GvHD of
the skin but consecutively the anemia resolved. Conclusion:
In these informative situations DLI documented their efﬁ-
cacy in correcting a misbalanced immune system after
allo-SCT. While in the MRD situation remaining tumor
cells vanished with increasing doses of DLI exactly when
ﬁrst signs of GvHD occurred, in the ABO incompatible sce-
nario few remaining host immune cells producing iso-
hemagglutinins were eradicated with a small dose of DLI.
This leads to the conclusion that donor immunosurveillance
